Because GLP-1 plays an important role in maintaining healthy blood glucose levels, a synthetic homolog of exendin-4, called exenatide (Byetta®), was developed in 2005 for type-2 diabetes treatment (see Figure 6). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.